Predictable Protection Made Easy*

The FilterWire EZ™ Embolic Protection System is meant to provide ease of use to make this system ideal for carotid artery stenting. With clinically proven safety and efficacy, the FilterWire EZ™ System is engineered to provide predictable outcomes.

Predictable Protection*

Clinically Proven

- 30-day BEACH¹ and CABERNET² trial results demonstrate safety and efficacy.

Captures Debris Effectively*

- 110 μm pore filter design permits continuous blood flow while maintaining embolic capture efficiency.
- Suspended nitinol filter loop provides 360° apposition in straight or tortuous anatomy.*

Ease of Use

Promotes Procedural Efficiency

- Peel-away delivery sheath with pre-loaded protection wire designed to simplify device preparation while providing rapid exchange convenience.
- Radiopaque loop designed for full deployment verification with one angiographic view.

Eases Crossing and Retrieval

- 3.2F (1.1mm) delivery sheath crossing profile and silicone-coated tip designed to facilitate crossing of lesions.
- Retrieval sheath designed for maximum filter coverage while withdrawing through deployed stent.
- Nitinol filter loop closes for effective particle retention during retrieval.

Simplifies Filter Sizing

- One size provides protection in vessels with 3.5mm to 5.5mm diameter landing zone.

BEACH 30-Day Major Adverse Event Rates¹

<table>
<thead>
<tr>
<th>Event</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite 30-Day</td>
<td>5.6%</td>
</tr>
<tr>
<td>Death</td>
<td>1.5%</td>
</tr>
<tr>
<td>Stroke</td>
<td>4.2%</td>
</tr>
<tr>
<td>- Minor Ipsilateral</td>
<td>1.9%</td>
</tr>
<tr>
<td>- Major Ipsilateral</td>
<td>1.0%</td>
</tr>
<tr>
<td>MI Rate</td>
<td>0.8%</td>
</tr>
</tbody>
</table>

Technical Success 97.1%

N=480

CABERNET 30-Day Major Adverse Event Rates²

<table>
<thead>
<tr>
<th>Event</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite 30-Day</td>
<td>3.9%</td>
</tr>
<tr>
<td>Death</td>
<td>0.5%</td>
</tr>
<tr>
<td>Stroke</td>
<td>3.4%</td>
</tr>
<tr>
<td>- Minor Ipsilateral</td>
<td>2.1%</td>
</tr>
<tr>
<td>- Major Ipsilateral</td>
<td>1.3%</td>
</tr>
<tr>
<td>MI Rate</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

Technical Success 99.1%

N=443

*Data on file, Boston Scientific Corporation.
Polyurethane filter – 110 micron pore size

Spinner tube
Catheter stop
Radiopaque spring coil tip
Radiopaque NiTi Loop

PTFE coated wire 0.014” (0.356 mm)

Product Information
6F (2 mm) Guide Catheter or Sheath-Compatible (minimum ID 0.066” / 1.68 mm)

<table>
<thead>
<tr>
<th>Order Number</th>
<th>Description</th>
<th>Crossing Profile</th>
<th>Vessel Diameter Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>H749 20105-190 0</td>
<td>FilterWire EZ System, 190cm*</td>
<td>3.2F (1.1mm, 0.042”)</td>
<td>3.5mm-5.5mm</td>
</tr>
<tr>
<td>H749 20105-300 0</td>
<td>FilterWire EZ System, 300cm</td>
<td>3.2F (1.1mm, 0.042”)</td>
<td>3.5mm-5.5mm</td>
</tr>
<tr>
<td>H749 50100-150 0</td>
<td>EZ Bent Tip Retrieval Sheath</td>
<td>4.0F (1.3mm, 0.052”)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Compatible with AddWire™ Extension Wire order code H749 22150-010.

Carotid Solutions from Boston Scientific

Boston Scientific offers great depth of technology specifically designed to address challenges of carotid artery disease. From surgical to endovascular options, Boston Scientific delivers tools physicians need to provide the right treatment to patients.

BEACH Trial Objective: To evaluate the outcomes of patients with carotid artery stenosis at high risk for carotid endarterectomy (CEA) using the Carotid WALLSTENT™ Monorail™ Endoprosthesis and the FilterWire EX™ and FilterWire EZ™ Embolic Protection Systems.

Primary Endpoints: A 1-year composite endpoint of cumulative morbidity and mortality that included:
- ≤ 24 hours: all non-Q-wave Myocardial Infarction (MI)
- ≤ 30 days: all Q-wave MI, all Death, all Stroke
- >30 days, ≤ 1 year: Isolated Stroke and Neurological Death

BEACH 1-Year Major Adverse Event Rates:
Pivotal Group: 9.1%‡
- Death: 3.2%
- Stroke: 7.0%
- MI: 1.1%
‡Patients may have had more than one event.

System Technical Success includes FilterWire EZ™ System Technical Success combined with Carotid WALLSTENT™ Monorail™ Endoprosthesis Technical Success and is calculated on the number of system placement attempts.

Primary Endpoint #2:
0-365 days (1 year): all Death, all Stroke, all MI (Q and non-Q-wave). Note: All D/S/MI means any death, stroke or MI that is related or NOT related to the target treated lesion/vessel.

BEACH 30-Day Major Adverse Event Rates:
Pivotal Group: 5.6%‡
- Death: 1.5%
- Stroke: 4.2%
- MI: 0.8%
‡Patients may have had more than one event.

CABERNET Trial Objective:
To evaluate the safety and efficacy of the NexStent™ Monorail™ Carotid Stent and Delivery System and the Boston Scientific FilterWire EX™ and FilterWire EZ™ Embolic Protection Systems by assessing the outcomes of patients with carotid artery stenosis in the ICA, CCA or ICA/CCA bifurcation who are at high risk for carotid endarterectomy (CEA).

Primary Endpoint #1
A composite major adverse event rate including:
- 0-30 days: all Death, Stroke and MI (Q and non-Q-wave), plus Isolated Stroke, including any death related to isolated stroke, from 31-365 days (1 year).

CABERNET 1-Year Major Adverse Event Rates:
Pivotal Group: 6.5%
- Death: 0.5%
- Stroke: 4.0%
- MI: 0.3%
- Patients may have had more than one event.

Primary Endpoint #2
0-365 days (1 year): all Death, all Stroke, all MI (Q and non-Q-wave).
Note: All D/S/MI means any death, stroke or MI that is related or NOT related to the target treated lesion/vessel.
For example, if a patient died of cancer, their death was included in the final calculation.

1-Year Major Adverse Event Rates:
Pivotal Group: 11.5%
- Death: 4.5%
- Stroke: 5.0%
- MI: 2.0%
‡ Patients may have had more than one event.
‡‡ No neurological death.

BEACH is a study sponsored by Boston Scientific Corporation.
CABERNET is a registry sponsored by Boston Scientific Corporation.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use only in countries with applicable health authority product registrations.

BEACH is a study sponsored by Boston Scientific Corporation.
CABERNET is a registry sponsored by Boston Scientific Corporation.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use only in countries with applicable health authority product registrations.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use only in countries with applicable health authority product registrations.

Boston Scientific
Defining tomorrow, today.
© 2011 Boston Scientific Corporation or its affiliates. All rights reserved.
DINPER2147EC